At what gestational age can the abortion pill, consisting of mifepristone (anti-progestin) followed by misoprostol (prostaglandin E1 analog), be used for pregnancy termination?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Gestational Age Limits for Medication Abortion

The abortion pill (mifepristone followed by misoprostol) can be used up to 77 days (11 weeks) of gestation for medication abortion, though some evidence supports use up to 84 days (12 weeks) for early pregnancy loss. 1

Standard Gestational Age Limits

  • Up to 63 days (9 weeks) of amenorrhea is the most commonly cited limit in clinical practice, with this timeframe supported by extensive research demonstrating high efficacy and safety 2, 3
  • Up to 77 days (11 weeks) of gestation represents the current evidence-based upper limit for medication abortion specifically 1
  • Up to 84 days (12 weeks) of gestation is supported for management of early pregnancy loss (miscarriage) using the same medication regimen 1

Efficacy by Gestational Age

  • Before 9 weeks: Medical abortion can be performed safely in outpatient or home settings with complete abortion rates of 95-97% 4, 3
  • 9-11 weeks: The medication regimen remains effective, though success rates may be slightly lower than earlier gestations 5, 1
  • Second trimester (beyond 12 weeks): Labor induction abortion using mifepristone and misoprostol is effective throughout the second trimester, though this represents a different clinical scenario with different dosing protocols 6

Standard Dosing Regimen

  • Mifepristone 200 mg orally followed by misoprostol 800 mcg administered buccally or vaginally 1
  • The interval between medications can be simultaneous to 48 hours, with 24-48 hours being most common, though simultaneous administration has been shown equally effective 2, 3
  • For second trimester procedures, mifepristone 200 mg is followed by misoprostol 24-48 hours later, with 95% of abortions complete within 24 hours of misoprostol administration 6

Important Clinical Considerations

Gestational age determination is critical and should be established using:

  • Ultrasonography when available and clinically indicated 1
  • Menstrual history when ultrasonography cannot be confirmed or when there are no risk factors for ectopic pregnancy 1
  • Ultrasonography is specifically needed when gestational dating cannot be confirmed using clinical data alone or when risk factors for ectopic pregnancy exist 1

Key Safety Points

  • Contraindications: Misoprostol should be avoided in women with previous cesarean delivery due to risk of uterine rupture 7
  • Expected effects: Cramping and bleeding are normal, with bleeding lasting an average of 9-16 days 1
  • Rare complications include ongoing pregnancy, infection, hemorrhage, undiagnosed ectopic pregnancy, and need for unplanned uterine aspiration 1

Access Considerations

  • The Society for Maternal-Fetal Medicine supports access to abortion without unnecessary barriers, including via telemedicine 8
  • When requiring in-person testing would delay or limit abortion access, the priority is completing the abortion, with patients counseled on potential implications 8
  • Mifepristone and misoprostol can be offered in ambulatory settings without special equipment or on-site emergency services given their safety profile 5

References

Research

Pregnancy termination.

Steroids, 2000

Guideline

Aborto: Etiología, Clasificación, Características Clínicas, Diagnóstico y Tratamiento

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Medication to Manage Abortion and Miscarriage.

Journal of general internal medicine, 2020

Guideline

Medical Termination of Pregnancy (MTP) Kit Dosing Recommendations

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.